Summary:
Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-
Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous
Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients.
Qualified Participants Must:
• Moderate to severe atopic dermatitis (confirmed by a dermatologist) according to the Hannifin and Rajka criteria or Eichenfield revised criteria
•
Onset of AtD symptoms occurring at least 6 months prior to Screening, with stable disease for at least 1 month prior to Screening